Previous studies have shown the prognostic benefit of N-terminal probrain natriuretic peptide (NTpro-BNP) in pulmonary arterial hypertension (PAH) at time of diagnosis. However, there are only limited data on the clinical utility of serial measurements of the inactive peptide NTpro-BNP in PAH. This study examined the value of serial NTpro-BNP measurements in predicting prognosis PAH. We retrospectively analyzed all available NTpro-BNP plasma samples in 198 patients who were diagnosed with World Health Organization group I PAH from January 2002 through January 2009. At time of diagnosis median NTpro-BNP levels were significantly different between survivors (610 pg/ml, range 6 to 8,714) and nonsurvivors (2,609 pg/ml, range 28 to 9,828, p <0.001). In addition, NTpro-BNP was significantly associated (p <0.001) with other parameters of disease severity (6-minute walking distance, functional class). Receiver operating curve analysis identified <1,256 pg/ml as the optimal NTpro-BNP cutoff for predicting mortality at time of diagnosis. Serial measurements allowed calculation of baseline NTpro-BNP (i.e., intercept obtained by back-extrapolation of concentrationtime graph), providing a better discrimination between survivors and nonsurvivors than NTpro-BNP at time of diagnosis alone (p = 0.010). Furthermore, a decrease of NTpro-BNP of >15%/year was associated with survival. In conclusion, a serum NTpro-BNP level <1,256 pg/ml at time of diagnosis identifies poor outcome in patients with PAH. In addition, a decrease in NTpro-BNP of >15%/year is associated with survival in PAH.,
The American Journal of Cardiology
Erasmus MC: University Medical Center Rotterdam

Mauritz, G.-J., Rizopoulos, D., Groepenhoff, H., Tiede, H., Felix, J., Eilers, P., … Vonk-Noordegraaf, A. (2011). Usefulness of serial N-terminal ProB-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. The American Journal of Cardiology, 108(11), 1645–1650. doi:10.1016/j.amjcard.2011.07.025